Skip to content
Episealer® Knee Implant presented at British knee congress

Episurf Medical (Nasdaq: EPIS B) today announces that the Episealer® Knee Implant technology was presented as a part of the scientific program at the British focus meeting Sports Knee Surgery 2021. The presentation, “Episealer Mini-Metal implant – technique and indication” was presented by Dr. med. Johannes Holz from Orthocentrum, Park-Klinik Manhagen, Hamburg, Germany, and discussed patient selection, surgical technique and clinical evidence. The Sports Knee Surgery 2021 congress was held in Coventry, UK, on November 5, and addressed “How and Why” for specific techniques in knee surgery.

We have known for a long time that patients who have received an Episealer® Knee Implant can often go back to an active lifestyle with sports activities. The fact that the Episealer® is recognised at this focused sports knee meeting, confirms to us that the orthopaedic societies share our experience and find our technology useful for the treatment of the challenging gap patients which are too old for biological treatments and too young for prosthesis surgery”, says Pål Ryfors, CEO Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

CisionBlockPro\Cision\FeedItem Object
(
    [HtmlCompanyInformation:protected] => <p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><strong><span style="font-size:10pt">About Episurf Medical</span></strong></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><em>Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.</em></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"></p>
    [HtmlContact:protected] => <p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><strong><span style="font-size: 10pt; font-family: arial,helvetica,sans-serif;">For more information, please contact:</span></strong></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">P&aring;l Ryfors, CEO, Episurf Medical<br /></span><span style="font-size: 10pt; font-family: arial,helvetica,sans-serif;">Tel:</span><span style="font-size: 10pt;">+46 (0) 709 62 36 69<br /></span><span style="font-size: 10pt;">Email:&nbsp;</span><a href="mailto:pal.ryfors@episurf.com">pal.ryfors@episurf.com</a></p>
    [HtmlTitle:protected] => <h1 style="line-height:120%;"><span style="font-family:arial,helvetica,sans-serif"><strong>Episealer&reg; Knee Implant presented at British knee congress</strong></span></h1>
    [HtmlHeader:protected] => 
    [HtmlIntro:protected] => 
    [Body:protected] => Episurf Medical (Nasdaq: EPIS B) today announces that the Episealer® Knee Implant technology was presented as a part of the scientific program at the British focus meeting Sports Knee Surgery 2021. The presentation, “Episealer Mini-Metal implant – technique and indication” was presented by Dr. med. Johannes Holz from Orthocentrum, Park-Klinik Manhagen, Hamburg, Germany, and discussed patient selection, surgical technique and clinical evidence. The Sports Knee Surgery 2021 congress was held in Coventry, UK, on November 5, and addressed “How and Why” for specific techniques in knee surgery.
"We have known for a long time that patients who have received an Episealer® Knee Implant can often go back to an active lifestyle with sports activities. The fact that the Episealer® is recognised at this focused sports knee meeting, confirms to us that the orthopaedic societies share our experience and find our technology useful for the treatment of the challenging gap patients which are too old for biological treatments and too young for prosthesis surgery”, says Pål Ryfors, CEO Episurf Medical.
    [HtmlBody:protected] => <p style="margin-bottom:11px;margin-top:12px"><span><span style="font-size:11pt"><span><span style="font-family:arial,helvetica,sans-serif">Episurf Medical (Nasdaq: EPIS B) today announces that the Episealer® Knee Implant technology was presented as a part of the scientific program at the British focus meeting Sports Knee Surgery 2021. The presentation, “Episealer Mini-Metal implant – technique and indication” was presented by Dr. med. Johannes Holz from Orthocentrum, Park-Klinik Manhagen, Hamburg, Germany, and discussed patient selection, surgical technique and clinical evidence. The Sports Knee Surgery 2021 congress was held in Coventry, UK, on November 5, and addressed “How and Why” for specific techniques in knee surgery. </span></span></span></span></p>
<p style="margin-bottom:11px"><span><span style="font-size:11pt"><span><span style="font-family:arial,helvetica,sans-serif">"<em>We have known for a long time that patients who have received an Episealer® Knee Implant can often go back to an active lifestyle with sports activities. The fact that the Episealer® is recognised at this focused sports knee meeting, confirms to us that the orthopaedic societies share our experience and find our technology useful for the treatment of the challenging gap patients which are too old for biological treatments and too young for prosthesis surgery</em>”, says Pål Ryfors, CEO Episurf Medical.</span></span></span></span></p>
    [ServiceCategories:protected] => Array
        (
            [0] => CisionBlockPro\Cision\ServiceCategory Object
                (
                    [ServiceName:protected] => Twitter
                    [Name:protected] => Twitter
                    [Value:protected] => 9341
                )
            [1] => CisionBlockPro\Cision\ServiceCategory Object
                (
                    [ServiceName:protected] => LinkedIn
                    [Name:protected] => LinkedIn
                    [Value:protected] => 12311
                )
            [2] => CisionBlockPro\Cision\ServiceCategory Object
                (
                    [ServiceName:protected] => Facebook
                    [Name:protected] => Facebook
                    [Value:protected] => 9307
                )
        )
    [LogoUrl:protected] => https://mb.cision.com/Public/14691/logo/96c29c854b230ac3_org.png
    [CompanyInformation:protected] => About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
    [Contact:protected] => For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
    [Header:protected] => 
    [Keywords:protected] => Array
        (
            [0] => Episurf Medical
            [1] => EpiSurf
        )
    [QuickFacts:protected] => Array
        (
        )
    [Categories:protected] => Array
        (
        )
    [Videos:protected] => Array
        (
        )
    [Files:protected] => Array
        (
            [0] => CisionBlockPro\Cision\File Object
                (
                    [IsMain:protected] => 1
                    [MediaType:protected] => File
                    [Url:protected] => https://mb.cision.com/Main/14691/3449682/1493272.pdf
                    [FileName:protected] => wkr0006.pdf
                    [Title:protected] => Episealer® Knee Implant presented at British knee congress
                    [Description:protected] => Episealer® Knee Implant presented at British knee congress
                    [CreateDate:protected] => 2021-11-09T08:15:05.07Z
                    [Keywords:protected] => Array
                        (
                        )
                    [Extension:protected] => pdf
                )
        )
    [Quotes:protected] => Array
        (
        )
    [ExternalLinks:protected] => Array
        (
        )
    [EmbeddedItems:protected] => Array
        (
        )
    [Id:protected] => 4110650
    [EncryptedId:protected] => B14CFF19E8B5AECD
    [IsRegulatory:protected] => 
    [PublishDate:protected] => 2021-11-09T08:15:00Z
    [LastChangeDate:protected] => 2021-11-09T08:15:05.037Z
    [Title:protected] => Episealer® Knee Implant presented at British knee congress
    [Intro:protected] => 
    [IptcCode:protected] => 04016003
    [InformationType:protected] => PRM
    [LanguageCode:protected] => en
    [CountryCode:protected] => se
    [CanonicalUrl:protected] => 
    [CisionWireUrl:protected] => https://news.cision.com/episurf/r/episealer--knee-implant-presented-at-british-knee-congress,c3449682
    [LanguageVersions:protected] => Array
        (
        )
    [Images:protected] => Array
        (
        )
    [Tickers:protected] => Array
        (
            [0] => stdClass Object
                (
                    [Symbol] => EPIS B
                    [ISIN] => SE0003491562
                    [PrimaryListing] => 1
                    [IsShare] => 1
                    [MarketPlaceSymbol] => STO
                    [MarketPlaceName] => Stockholmsbörsen
                    [MarketPlaceBloombergCode] => SS
                    [MarketPlaceMarketWireCode] => OMX
                    [MarketPlaceIsRegulated] => 1
                    [MarketPlaceCountryCode] => SE
                )
        )
)